|
| ID |
DDInter714 |
| Drug Type |
small molecule |
| Molecular Formula |
C27H36N6O3S |
| Molecular Weight |
524.690
|
| Description |
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative.[A183188]
Fedratinib was granted FDA approval on August 16, 2019.[L8090]
|
| ATC Classification |
L01XE57
|
| IUPAC Name |
N-Tert-Butyl-3-{[5-Methyl-2-({4-[2-(Pyrrolidin-1-Yl)Ethoxy]Phenyl}Amino)Pyrimidin-4-Yl]Amino}Benzene-1-Sulfonamide |
| InChI |
Inchi=1S/C27H36N6O3S/C1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/H7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31) |
| InChI Key |
JOOXLOJCABQBSG-UHFFFAOYSA-N |
| Canonical SMILES |
CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C |
| Useful Links |
DrugBank
ChEMBL
PubChem
|